MCID: PST020
MIFTS: 41

Postpoliomyelitis Syndrome

Categories: Rare diseases, Neuronal diseases, Infectious diseases, Muscle diseases

Aliases & Classifications for Postpoliomyelitis Syndrome

MalaCards integrated aliases for Postpoliomyelitis Syndrome:

Name: Postpoliomyelitis Syndrome 12 53 59 44 15 73
Postpolio Syndrome 12 53 59
Post-Polio Syndrome 76 54
Post-Polio Muscular Atrophy 53
Post-Poliomyelitic Syndrome 53
Postpoliomyelitic Syndrome 59
Postpoliomyelitis Sequelae 59
Post Polio Syndrome 53
Post-Polio Sequelae 53
Polio Late Effects 53
Postpolio Sequelae 59

Characteristics:

Orphanet epidemiological data:

59
postpoliomyelitis syndrome
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4952
ICD10 33 G14
MeSH 44 D016262
SNOMED-CT 68 31097004 367094007
Orphanet 59 ORPHA2942
ICD10 via Orphanet 34 G14
UMLS via Orphanet 74 C0080040
UMLS 73 C0080040

Summaries for Postpoliomyelitis Syndrome

NINDS : 54 Post-polio syndrome (PPS) is a condition that affects polio survivors many years after recovery from an initial attack of the poliomyelitis virus. PPS is characterized by a further weakening of muscles that were previously affected by the polio infection. The most common symptoms include slowly progressive muscle weakness, fatigue (both general and muscular), and a decrease in muscle size (muscular atrophy). Pain from joint deterioration and increasing skeletal deformities such as scoliosis are common. Some individuals experience only minor symptoms, while others develop more visible muscle weakness and atrophy.  PPS is rarely life-threatening but the symptoms can interfere significantly with the individual's capacity to function independently.   While polio is contagious, PPS is not transmissible.  Only a polio survivor can develop PPS.

MalaCards based summary : Postpoliomyelitis Syndrome, also known as postpolio syndrome, is related to lateral sclerosis and amyotrophic lateral sclerosis 1, and has symptoms including muscle weakness, muscle pain and sleep apnea. An important gene associated with Postpoliomyelitis Syndrome is TARDBP (TAR DNA Binding Protein). The drugs Modafinil and Armodafinil have been mentioned in the context of this disorder. Affiliated tissues include muscle, brain and skeletal muscle, and related phenotypes are muscle weakness and arthralgia

Disease Ontology : 12 A poliomyelitis that results in atrophy located in muscle, many years after the initial infection, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3. It is characterized by new weakening in muscles that were previously affected by the polio infection and in muscles that were unaffected. The infection has symptom muscle weakness, has symptom muscle pain, has symptom sleep apnea, and has symptom breathing problems.

NIH Rare Diseases : 53 Post polio syndrome (PPS) is a condition that affects polio survivors years after recovery from the initial polio illness. Symptoms and severity vary among affected people and may include muscle weakness and a gradual decrease in the size of muscles (atrophy); muscle and joint pain; fatigue; difficulty with gait; respiratory problems; and/or swallowing problems. Only a polio survivor can develop PPS. While polio is a contagious disease, PPS is not. The exact cause of PPS years after the first episode of polio is unclear, although several theories have been proposed. Treatment focuses on reducing symptoms and improving quality of life.

Wikipedia : 76 Post-polio syndrome (PPS, or post-poliomyelitis syndrome or post-polio sequelae) is a condition that... more...

Related Diseases for Postpoliomyelitis Syndrome

Graphical network of the top 20 diseases related to Postpoliomyelitis Syndrome:



Diseases related to Postpoliomyelitis Syndrome

Symptoms & Phenotypes for Postpoliomyelitis Syndrome

Symptoms:

12
  • muscle weakness
  • muscle pain
  • sleep apnea
  • breathing problems

Human phenotypes related to Postpoliomyelitis Syndrome:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001324
2 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
3 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
4 difficulty climbing stairs 59 32 frequent (33%) Frequent (79-30%) HP:0003551
5 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
6 hypersomnia 59 32 frequent (33%) Frequent (79-30%) HP:0100786
7 dysarthria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001260
8 abnormal joint morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0001367
9 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
10 respiratory insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0002093
11 fasciculations 59 32 occasional (7.5%) Occasional (29-5%) HP:0002380
12 skeletal muscle atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0003202
13 muscle cramps 59 32 occasional (7.5%) Occasional (29-5%) HP:0003394
14 hypoventilation 59 32 very rare (1%) Very rare (<4-1%) HP:0002791
15 pain 59 Very frequent (99-80%)
16 abnormality of higher mental function 59 Frequent (79-30%)
17 sleep disturbance 59 Occasional (29-5%)

Drugs & Therapeutics for Postpoliomyelitis Syndrome

Drugs for Postpoliomyelitis Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
2
Armodafinil Approved, Investigational Phase 3 112111-43-0
3 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 3
4 gamma-Globulins Phase 2, Phase 3,Phase 3
5 Pharmaceutical Solutions Phase 3,Phase 2
6 Antibodies Phase 2, Phase 3,Phase 3,Not Applicable
7 Immunoglobulins Phase 2, Phase 3,Phase 3,Not Applicable
8 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 3
9 Central Nervous System Stimulants Phase 3
10 Cytochrome P-450 CYP3A Inducers Phase 3
11 Wakefulness-Promoting Agents Phase 3
12 Antioxidants Not Applicable

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg) Completed NCT00231439 Phase 2, Phase 3 IvIg
2 Intravenous Immunoglobulins for Post-Polio Syndrome Completed NCT01537575 Phase 3
3 Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome Recruiting NCT02176863 Phase 2, Phase 3
4 L-Citrulline in Patients With Post-Polio Syndrome Active, not recruiting NCT02801071 Phase 3 15g L-citrulline daily p.o.;Placebo
5 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
6 A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome Withdrawn NCT01549847 Phase 3 L-carnitine and piracetam;Placebo
7 Study of Mental Fatigue in Polio Survivors Unknown status NCT00487487
8 Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) Completed NCT00160082 Not Applicable Xepol
9 Study of "Post-Polio Syndrome" Completed NCT00001185
10 Glutathione and Health With Post-Polio Syndrome Completed NCT01402570 Not Applicable
11 Arm Cycling to Improve Fitness in Polio Survivors Completed NCT01271530 Not Applicable
12 Enhance Wellness for Individuals With Long-Term Physical Disabilities Completed NCT02815878 Not Applicable
13 Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio Patients Completed NCT03064711 Not Applicable
14 Electromyography to Diagnose Neuromuscular Disorders Completed NCT00004553 Not Applicable
15 Brain Physiology in Polio Survivors Completed NCT00080600
16 Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders Completed NCT00001220
17 Clinical Trial of a Serious Game for Individuals With SCI/D Completed NCT02341950 Not Applicable
18 Characterization of the Immunological Profile Patients With Post-polio Syndrome Recruiting NCT03396783 Not Applicable
19 Spinal Cord Gray Matter Imaging in Post Polio Syndrome Active, not recruiting NCT03561623
20 Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis Active, not recruiting NCT02089880 Not Applicable

Search NIH Clinical Center for Postpoliomyelitis Syndrome

Cochrane evidence based reviews: postpoliomyelitis syndrome

Genetic Tests for Postpoliomyelitis Syndrome

Anatomical Context for Postpoliomyelitis Syndrome

The Foundational Model of Anatomy Ontology organs/tissues related to Postpoliomyelitis Syndrome:

19
Muscle

MalaCards organs/tissues related to Postpoliomyelitis Syndrome:

41
Brain, Skeletal Muscle, Spinal Cord, Testes

Publications for Postpoliomyelitis Syndrome

Articles related to Postpoliomyelitis Syndrome:

(show all 21)
# Title Authors Year
1
Pyridostigmine: Postpoliomyelitis Syndrome. ( 27303089 )
2016
2
Brain Volume and Fatigue in Patients With Postpoliomyelitis Syndrome. ( 24060387 )
2013
3
Role of medical rehabilitation in postpoliomyelitis syndrome. A case report. ( 26527937 )
2013
4
Overcoming barriers to work participation for patients with postpoliomyelitis syndrome. ( 20624037 )
2011
5
Exercise therapy and cognitive behavioural therapy to improve fatigue, daily activity performance and quality of life in postpoliomyelitis syndrome: the protocol of the FACTS-2-PPS trial. ( 20082714 )
2010
6
Energy demands of walking in persons with postpoliomyelitis syndrome: relationship with muscle strength and reproducibility. ( 16401452 )
2006
7
A comparison of fatigue scales in postpoliomyelitis syndrome. ( 16935057 )
2006
8
Walking in postpoliomyelitis syndrome: the relationships between time-scored tests, walking in daily life and perceived mobility problems. ( 16040470 )
2005
9
Reproducibility of walking at self-preferred and maximal speed in patients with postpoliomyelitis syndrome. ( 15605328 )
2004
10
Motor unit characteristics in healthy subjects and those with postpoliomyelitis syndrome: a high-density surface EMG study. ( 15318337 )
2004
11
A comparison of 4 questionnaires to measure fatigue in postpoliomyelitis syndrome. ( 15031823 )
2004
12
Reproducibility of maximal quadriceps strength and its relationship to maximal voluntary activation in postpoliomyelitis syndrome. ( 15295752 )
2004
13
Perceived health and physical functioning in postpoliomyelitis syndrome: a 6-year prospective follow-up study. ( 12881833 )
2003
14
Predictive factors and correlates for pain in postpoliomyelitis syndrome patients. ( 12161832 )
2002
15
Laryngeal manifestations of postpoliomyelitis syndrome. ( 11411483 )
2001
16
Twenty-one patients with strictly defined postpoliomyelitis syndrome: no poliovirus-specific IgM antibodies in the cerebrospinal fluid. ( 8024252 )
1994
17
Excessive muscular fatigue in the postpoliomyelitis syndrome. ( 8164817 )
1994
18
Postpoliomyelitis syndrome problems of knee function: a review. ( 8829592 )
1993
19
Neurologically normal patients with suspected postpoliomyelitis syndrome: electromyographic assessment of past denervation. ( 2059122 )
1991
20
Ventilator management in Duchenne muscular dystrophy and postpoliomyelitis syndrome: twelve years' experience. ( 2647055 )
1989
21
Vocal cord paralysis in postpoliomyelitis syndrome. ( 3613801 )
1987

Variations for Postpoliomyelitis Syndrome

Expression for Postpoliomyelitis Syndrome

Search GEO for disease gene expression data for Postpoliomyelitis Syndrome.

Pathways for Postpoliomyelitis Syndrome

GO Terms for Postpoliomyelitis Syndrome

Biological processes related to Postpoliomyelitis Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of insulin secretion GO:0032024 8.62 BLK TARDBP

Sources for Postpoliomyelitis Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....